The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency.
Claudio JommiCarlotta GaleonePublished in: PharmacoEconomics - open (2023)
Innovativeness status is driven by the added therapeutic value and quality of evidence. The appraisal process is internally consistent and predictable. This provides industry with a clear indication of what is needed to ensure that access to their medicines is prioritized.